Blueprint Medicines Corporation (NASDAQ:BPMC): When Will It Breakeven?
Piper Sandler Keeps Their Hold Rating on Blueprint Medicines (BPMC)
Stifel Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $150
Stifel Nicolaus Remains a Buy on Blueprint Medicines (BPMC)
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
Oppenheimer's Best SMID-cap Ideas: AI, Health, Obesity Drugs, and More
Express News | Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115
Blueprint Medicines (BPMC) Receives a Hold From Morgan Stanley
Oppenheimer's Best 'SMID-cap' Ideas for 2024
Blueprint Medicines(BPMC.US) Officer Sells US$1.41 Million in Common Stock
Oppenheimer Adjusts Price Target on Blueprint Medicines to $125 From $114, Maintains Outperform Rating
Blueprint Medicines Is Maintained at Outperform by Oppenheimer
Oppenheimer Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $125
Express News | Blueprint Medicines : Oppenheimer Raises Target Price to $125 From $114
Oppenheimer Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Raises Target Price to $125
Blueprint Medicines(BPMC.US) Officer Sells US$37,012.95 in Common Stock
Blueprint Medicines Insiders Sell US$7.2m Of Stock, Possibly Signalling Caution
Expert Ratings For Blueprint Medicines
Needham Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $130
Blueprint Medicines Price Target Maintained With a $130.00/Share by Needham